Botulinum toxin type A for the management of glabellar rhytids

Clinical, Cosmetic and Investigational Dermatology

Volumn 3, Issue , 2010, Pages 15-23

  Tremaine, Anne Marie ^a   McCullough, Jerry L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Botox; Botulinum toxin type A; Complications; Dosing; Dysport; Glabella

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AZZALURE; BOTULINUM TOXIN A; COSMETOX; HUMAN ALBUMIN; LACTOSE; LIDOCAINE; NEURONOX; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RT 001; RT 002; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AGING; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHEMA; EYE BURNING; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; GLABELLAR RHYTID; HUMAN; MINIMALLY INVASIVE PROCEDURE; REVIEW; SKIN; UNITED STATES;

EID: 77953450644     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/ccid.s6492     Document Type: Review

References (66)

1. The American Society for Aesthetic Plastic Surgery. Cosmetic surgery national data bank. Available at http://www.surgery.org/sites/default/files/2008stats.pdf (Accessed October 8, 2009).
2. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31(4):414-422.
3. Fagien S, Carruthers JD. A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures. Plast Reconstr Surg. 2008;122(6):1915-1925.
4. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17-21.
5. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996;35(4):569-572.
6. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994;94(1):94-99.
7. Hankins C. Strimling R. Rogers G. Botulinum A toxin for glabellar wrinkles. Dose and response. Dermatol Surg. 1998;24(11): 1181-1183.
8. Olver JM. Botulinum toxin A treatment of overactive corrugator super-cilii in thyroid eye disease. Br Med J. 1998;82:528-533.
9. Erian A, Ionescu NE. Combination treatment of glabellar rhytids. Int J Cosmet Surg. 1999;7:14-17.
10. Feller G, Bayerl C, Jung E, Rzany B. Treatment of dynamic facial wrinkles with botulinum toxin type A (Dysport™)-a pilot study. Akt Dermatol. 2000;26:65-69.
11. Le Louarn C. Botulinum toxin and facial wrinkles: a new injection procedure. Ann Chir Plast Esthet. 1998;43:526-533.
12. Ascher B, Klap P, Marion MH, Chanteloub F. Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles: an initial study. Ann Chir Plast Esthet. 1995;40:67-76.
13. Carruthers J, Lowe N, Menter M, Gibson J, Eadie N; Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112(4):1089-1098.
14. Carruthers J, Lowe N, Menter M, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840-849.
15. Monheit GD, Cohen JL; Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol. 2009;61(3):421-425.
16. Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type a (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3 randomized, double-blind, placebo controlled study. Plast Reconstr Surg. 2009;124(5):1619-1629.
17. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35:1-9.
18. Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11(2):77-83.
19. Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8(5):439-444.
20. Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Caird D; German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg. 2007; 33(1 Spec No.):S18-S25.
21. Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg. 2002;26(5):356-359.
22. Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol. 2009;48(7):768-776.
23. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-990.
24. Botox® Cosmetic [Product information package insert]. (72284US10A) Irvine, CA: Allergan Inc.;2009.
25. Dysport™ [Product information package insert]. Scottsdale, AZ: Medicis Aesthetics Inc.; 2009.
26. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1 Spec No.):S51-S59.
27. Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg. 2009;35(3):429-435.
28. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31(10):1297-1303.
29. Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. J Am Acad Dermatol. 2009;60(6):972-979.
30. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51(2):223-233.
31. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142(3):320-326.
32. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol. 2006;55(6):975-980.
33. Lowe NJ. Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives. Dermatol Surg. 1998;24:1216-1218.
34. Lew H, Yun YS, Lee SY, Kim SJ. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica. 2002;216(1):50-54.
35. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009;25(7):1573-1584.
36. Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol. 2008;255(12):1932-1939.
37. Boyle M, McGwin G Jr, Flanagan C, Vicinanzo M, Long J. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference? Ophthal Plast Reconstr Surg. 2009;25(2):81-84.
38. Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg. 2007;33(1 Spec No.):S97-S104.
39. Carruthers A, Bogle M, Carruthers J, et al. A randomized, evaluator-blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type a in the treatment of lateral orbial rhytides. Dermatol Surg. 2007;33(5):567-571.
40. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140(11):1351-1354.
41. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon. 2009;54(5):683-689.
42. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40(3):374-380.
43. Kranz G, Haubenberger D, Voller B, et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord. 2009;24(2):231-236.
44. Zechmeister M, De Oliveira Dal'Forno T. Conservation, dilution, and storage after dilution. In: Hexel D, Trinidade de Almeida A, Editors. Cosmetic Use of Botulinum Toxin. Porto Alegre: AGE Editoria; 2002:43-44.
45. Alam M, Yoo SS, Wrone DA, White LE, Kim JY. Sterility assessment of multiple use botulinum A exotoxin vials: A prospective simulation. J Am Acad Dermatol. 2006;55(2):272-275.
46. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29(5):523-529.
47. Hexsel D, Rutowitsch MS, de Castro LC, do Prado DZ, Lima MM. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35(6):933-939.
48. Klein A. Complications with the use of botulinum toxin. Dermatol Clin. 2004;22(2):197-205.
49. Hexsel D. Mazzuco, Zechmeister M, et al. Complications and adverse effects: diagnosis and treatment. In: Hexel D, Trinidade de Almeida A, Editors. Cosmetic Use of Botulinum Toxin. Porto Alegre: AGE Editoria; 2002:233-239.
50. Pena MA, Alam M, Yoo SS. Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg. 2007;26(1):29-33.
51. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A. Am J Clin Dermatol. 2005;6(3):141-150.
52. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: A double-blind, randomized controlled trial. Arch Dermatol. 2002;138(4):510-514.
53. Alam M, Yoo SS, Wrone DA, White LE, Kim JY. Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation. J Am Acad Dermatol. 2006;55(2):272-275.
54. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-1360.
55. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32(4):213-218.
56. Carruthers J, Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg. 2007; 33(1 Spec No.):S10-S17.
57. Carruthers A, Carruthers J. Patient-reported outcomes with botulinum neurotoxin type A. J Cosmet Laser Ther. 2007;9 (Suppl 1):32-37.
58. Carruthers A, Carruthers J. A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: Assessing patients' perception of treamtent outcomes. J Drugs Dermatol. 2009;8(10):924-929.
59. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33(1 Spec No.):S2-S9.
60. Galderma. Inc. Galderma 2009 News. Available at: http://www.galderma.com/News.asp?rub=40&Id=97. Accessed on November 12, 2009.
61. Revance Therapeutics, Inc. Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles. July 10, 2009. Available at: http://www.revance.com/401-news-publications?side. Accessed on November 5, 2009.
62. Jones T, Scott J, Tranowski D, Joshi T. Safety and Tolerability of Topical Botulinum Toxin Type A in Healthy Adults. Montreal, Canada: Poster session presented at 69th Annual Meeting of the Society for Investigative Dermatology; 2009 May 6-9.
63. Atamoros FP. Topical botulinum toxin type A for the treatment of moderate to severe lateral canthal lines: Preliminary safety and efficacy results of a blinded, randomized, placebo controlled trial. Boston, MA: Poster session presented at Summer Academy Meeting of the American Academy of Dermatology; 2009.
64. Chajchir I, Modi P, Chajchir A. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck. Aesthetic Plast Surg. 2008;32(5):715-722.
65. Modi P. Technical overview of topical botulinum toxin. Available at: http://www.transdermalcorp.com/images/TransdermalCorp-TopicalToxin-Business.ppt. Accessed on November 19, 2009.
66. Revance Therapeutics, Inc. Medicis and Revance announce agreement for development of next-gen neurotoxin. July 28, 2009. Available at: http://www.revance.com/401-news-publications?side. Accessed on November 5, 2009.